GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins

Robert J. Watson, Paul Bamborough, Heather Barnett, Chun‐wa Chung, Rob P. Davis, Laurie Gordon, Paola Grandi, M. Petretich, Alex Phillipou, Rab K. Prinjha,

Journal of Medicinal Chemistry · 2020 · 87 citations · 51 references

DOIFull text

Open access

Concepts

Abstract

Pan-bromodomain and extra terminal (BET) inhibitors interact equipotently with all eight bromodomains of the BET family of proteins. They have shown profound efficacy in vitro and in vivo in oncology and immunomodulatory models, and a number of them are currently in clinical trials where significant safety signals have been reported. It is therefore important to understand the functional contribution of each bromodomain to assess the opportunity to tease apart efficacy and toxicity. This article discloses the in vitro and cellular activity profiles of GSK789, a potent, cell-permeable, and highly selective inhibitor of the first bromodomains of the BET family.

References

51